Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion

被引:132
作者
Graumlich, JF
Ludden, TM
ConryCantilena, C
Cantilena, LR
Wang, YH
Levine, M
机构
[1] UNIV NEBRASKA,MED CTR,DEPT PHARMACEUT SCI,OMAHA,NE 68182
[2] NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892
[3] UNIFORMED SERV UNIV HLTH SCI,DIV CLIN PHARMACOL,BETHESDA,MD 20814
[4] NIDDKD,MOL & CLIN NUTR SECT,NIH,BETHESDA,MD 20892
[5] NIDDKD,INTRAMURAL NUTR PROGRAM,NIH,BETHESDA,MD 20892
关键词
ascorbic acid; pharmacokinetics; human; models-theoretical; models-nonlinear; bioavailability; ascorbic acid deficiency;
D O I
10.1023/A:1012186203165
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To develop a new pharmacokinetic model for ascorbic acid (vitamin C) since no previously published model describes ascorbic acid absorption and disposition over a broad physiologic range of doses and plasma concentrations. Methods. A new model was developed through exploratory simulations. The model was fitted to pharmacokinetic data obtained from seven healthy volunteers who underwent ascorbic acid depletion then gradual repletion. Concentrations of ascorbic acid were measured in plasma and urine. Final pharmacokinetic model parameter estimates were obtained using nonlinear regression analysis. Results. The new model included saturable absorption, distribution and renal tubular reabsorption parameters. The model described ascorbic acid concentrations in plasma, cells, and urine during depletion and gradual repletion phases with a residual error less than 15%. Conclusions. The model was useful for obtaining a new understanding of the likely causes for the complex concentration-time profile observed during gradual repletion. At doses of 200 to 2500 mg per day, the plateau in pre-dose concentrations is largely due to apparent saturation of tissue uptake and less a function of oral bioavailability and renal excretion than previously thought.
引用
收藏
页码:1133 / 1139
页数:7
相关论文
共 28 条
[21]   THE USE OF A NONLINEAR ABSORPTION-MODEL IN THE STUDY OF ASCORBIC-ACID BIOAVAILABILITY IN MAN [J].
PIOTROVSKIJ, VK ;
KALLAY, Z ;
GAJDOS, M ;
GERYKOVA, M ;
TRNOVEC, T .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1993, 14 (05) :429-442
[22]   The mechanism of the excretion of vitamin C by the human kidney [J].
Ralli, EP ;
Friedman, GJ ;
Rubin, SH .
JOURNAL OF CLINICAL INVESTIGATION, 1938, 17 (06) :765-770
[23]  
Rowland M., 2011, Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, V4th ed.
[24]  
WASHKO P, 1989, J BIOL CHEM, V264, P18996
[25]  
WASHKO PW, 1993, J BIOL CHEM, V268, P15531
[26]   ASCORBIC-ACID ACCUMULATION AND TRANSPORT IN HUMAN FIBROBLASTS [J].
WELCH, RW ;
BERGSTEN, P ;
BUTLER, JD ;
LEVINE, M .
BIOCHEMICAL JOURNAL, 1993, 294 :505-510
[27]   ASCORBIC-ACID ELIMINATION IN HUMANS AFTER INTRAVENOUS ADMINISTRATION [J].
YUNG, S ;
MAYERSOHN, M ;
ROBINSON, JB .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (10) :1491-1492
[28]   PHARMACOKINETICS OF ASCORBIC-ACID IN MAN [J].
ZETLER, G ;
SEIDEL, G ;
SIEGERS, CP ;
IVEN, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 10 (3-4) :273-282